Key result
Freedom Solo stentless valves are linked to more severe platelet loss than Mitroflow stented valves.
Why the study?
Does the Sorin Freedom Solo stentless bioprosthesis cause more severe thrombocytopenia compared to the Sorin Mitroflow stented bioprosthesis in patients undergoing aortic valve replacement?
Cohort (n=40)
Does the Sorin Freedom Solo stentless bioprosthesis cause more severe thrombocytopenia compared to the Sorin Mitroflow stented bioprosthesis in patients undergoing aortic valve replacement?
Absolute Event Rate: 25% vs 60%
Implantation of the Freedom Solo stentless bioprosthesis is associated with severe and prolonged thrombocytopenia compared to a stented bioprosthesis, requiring careful monitoring especially in patients receiving platelet inhibitors.
May warrant platelet monitoring with Freedom Solo; leaves open effects on bleeding risk and valve selection.
Stentless bioprostheses have been considered to achieve superior hemodynamics over stented bioprostheses for aortic valve replacement with improved long-term performance. We observed severe thrombocytopenia in patients who received the Sorin Freedom Solo aortic stentless pericardial bioprosthesis within the first days after implantation. Absolute and relative platelet counts within 2 weeks after implantation of either a stentless (Sorin Freedom Solo) or a stented (Sorin Mitroflow) bovine pericardial bioprosthesis were compared in a matched-pairs analysis in 40 patients. Except the preoperative values, absolute platelet count was higher at all time points in the Mitroflow group. In the Mitroflow group, the mean platelet count moderately dropped to a minimum of 60% of the initial value on POD 3 and fully recovered by POD 8. In the Freedom Solo group, platelet loss was significantly more severe (minimum relative value 25% on POD 4) with no recovery during follow-up (60% on POD 13). Eight patients of the Freedom Solo group experienced a critical platelet drop towards <20% of their initial values, in five of them absolute numbers decreased below 30,000/microl. No bleeding complications or other morbidity occurred. Attention should focus on the platelet count after implantation of the Freedom Solo bioprosthesis, especially in patients who are supposed to receive platelet inhibitors. However, the described phenomenon remains unexplained.
No takes yet. Share an insight, caveat, or question.
Yerebakan et al. (2008) conducted a cohort in Aortic valve replacement (n=40). Sorin Freedom Solo stentless bioprosthesis vs. Sorin Mitroflow stented bioprosthesis was evaluated on Minimum relative platelet count after implantation. The Sorin Freedom Solo stentless bioprosthesis caused significantly more severe platelet loss (minimum 25% of initial value) compared to the Mitroflow stented valve (60% of initial value).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: